Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboxymethylcellulose + vitamin D
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Ophthalmic, Buccal
01
Overview
A combination of carboxymethylcellulose (CMC) and vitamin D used for the treatment of dry eye disease, particularly in patients with vitamin D deficiency. Clinical studies have shown that this combination leads to earlier and significant improvement in tear breakup time (TBUT), Schirmer's test values, and ocular surface disease index (OSDI) scores compared to carboxymethylcellulose alone.
02
Targets
VDR (Vitamin D receptor)
Beyond the preview
Go deeper on carboxymethylcellulose + vitamin D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboxymethylcellulose + vitamin D.